Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450–2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020;382:727–33.

Article  CAS  PubMed  Google Scholar 

Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382:1708–20.

Article  CAS  PubMed  Google Scholar 

https://covid19.who.int/. Accessed 18 Jun 2023.

Horita N, Fukumoto T. Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic. J Med Virol. 2023; https://doi.org/10.1002/jmv.28231.

Cohen LE, Spiro DJ, Viboud C. Projecting the SARS-CoV-2 transition from pandemicity to endemicity: epidemiological and immunological considerations. PLoS Pathog. 2022; https://doi.org/10.1371/journal.ppat.1010591.

• Conway R, Grimshaw AA, Konig MF, et al. SARS – CoV-2 Infection and COVID -19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis & Rheumatology. 2022;74:766–75. This systematic review and meta-analysis demonstrates higher risk for infection and mortality in patients with rheumatic diseases compared with the general population

Article  CAS  Google Scholar 

Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996-2011. Arthritis Care Res (Hoboken). 2015;67:1078–85.

Article  PubMed  Google Scholar 

Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017;76:2009–16.

Article  PubMed  Google Scholar 

Bournia V-K, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G, Vourli G, Paraskevis D, Tektonidou MG, Sfikakis PP. All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015–2019. RMD Open. 2021;7:e001694.

Article  PubMed  PubMed Central  Google Scholar 

Spihlman AP, Gadi N, Wu SC, Moulton VR. COVID-19 and systemic lupus erythematosus: focus on immune response and therapeutics. Front Immunol. 2020; https://doi.org/10.3389/fimmu.2020.589474.

• Wang Y, Guga S, Wu K, et al. COVID-19 and systemic lupus erythematosus genetics: a balance between autoimmune disease risk and protection against infection. PLoS Genet. 2022; https://doi.org/10.1371/journal.pgen.1010253. This study demonstrates the genetic association of TYK2 between patients with severe COVID-19 and those with systemic lupus erythematosus

Zhang Q, Liu Z, Moncada-Velez M, et al. (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 1979; https://doi.org/10.1126/science.abd4570.

Bastard P, Rosen LB, Zhang Q, et al. (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 1979; https://doi.org/10.1126/science.abd4585.

Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13:799–814.

Article  CAS  PubMed  Google Scholar 

Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–27.

Article  CAS  PubMed  Google Scholar 

Graña C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database of Systematic Reviews. 2022, 2023:CD015477.

Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https://covid.cdc.gov/covid-data-tracker

Google Scholar 

Felten R, Dubois M, Ugarte-Gil MF, et al. Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases. Lancet Rheumatol. 2021;3:e243–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21:162–77.

CAS  PubMed  PubMed Central  Google Scholar 

Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. Arthritis Rheumatol. 2023;75:E1–E16.

Article  PubMed  Google Scholar 

Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39–52.

Article  CAS  PubMed  Google Scholar 

Goulenok T, Francois C, Mendes C, Farhi F, Alexandra J-F, Rouzaud D, Papo T, Sacre K. Improving COVID-19 vaccine coverage in patients with autoimmune and inflammatory diseases. J Rheumatol. 2022;49:118–9.

Article  PubMed  Google Scholar 

Li YK, Lui MPK, Yam LL, Cheng CS, Tsang THT, Kwok WS, Chung HY. COVID-19 vaccination in patients with rheumatic diseases: vaccination rates, patient perspectives, and side effects. Immun Inflamm Dis. 2022;10:e589.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chevet B, Figueroa-Parra G, Yang JX, Hulshizer CA, Gunderson TM, Duong SQ, Putman MS, Barbour KE, Crowson CS, Duarte-García A. COVID-19 vaccine uptake among patients with systemic lupus erythematosus in the American Midwest: the Lupus Midwest Network (LUMEN). J Rheumatol. 2022;49(11):1276–82.

Figueroa-Parra G, Esquivel-Valerio JA, Santoyo-Fexas L, Moreno-Salinas A, Gamboa-Alonso CM, De Leon-Ibarra AL, Galarza-Delgado DA. Knowledge and attitudes about influenza vaccination in rheumatic diseases patients. Hum Vaccin Immunother. 2021;17:1420–5.

Article  PubMed  Google Scholar 

Loubet P, Kernéis S, Groh M, Loulergue P, Blanche P, Verger P, Launay O. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine. 2015;33:3703–8.

Article  PubMed  Google Scholar 

Tan SYS, Yee AM, Sim JJL, Lim CC. COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance. Rheumatology. 2022; https://doi.org/10.1093/rheumatology/keac604.

Felten R, Kawka L, Dubois M, Ugarte-Gil MF, Fuentes-Silva Y, Piga M, Arnaud L. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021;3:e613–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuki EFN, Borba EF, Pasoto SG, et al. Impact of distinct therapies on antibody response to <scp>SARS-CoV</scp> -2 vaccine in systemic lupus erythematosus. Arthritis Care Res. 2022;74:562–71.

Article  CAS  Google Scholar 

Heshin-Bekenstein M, Ziv A, Toplak N, et al. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Rheumatology. 2022;61:4263–72.

Article  CAS  PubMed  Google Scholar 

• Md Yusof MY, Arnold J, Saleem B, Vandevelde C, Dass S, Savic S, Vital EM, Emery P. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study. Lancet. Rheumatol. 2023;5:e88–98. SARS-CoV-2 breakthrough infection rate was high but severe COVID-19 disease rate was similar to any severe infection rate in RTX-treated patients who were vaccinated

CAS  Google Scholar 

Moyon Q, Sterlin D, Miyara M, et al. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis. 2022;81:575–83.

Article  CAS  PubMed  Google Scholar 

Izmirly PM, Kim MY, Samanovic M, et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS–CoV-2 vaccination. Arthritis and Rheumatology. 2022;74:284–94.

Article  CAS  PubMed  Google Scholar 

Garcia-Cirera S, Calvet J, Berenguer-Llergo A, et al. Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients. Sci Rep. 2022;12:14772.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ammitzbøll C, Bartels LE, Bøgh Andersen J, et al. Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol. 2021;3:622–8.

Article  PubMed  PubMed Central  Google Scholar 

• Thomas Κ, Grigoropoulos I, Alexopoulou P, et al. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2. Rheumatology. 2023; https://doi.org/10.1093/rheumatology/kead236. This study descibes cell-mediated immune responses as a vaccination efficacy marker against SARS-CoV-2 in RTX-treated patients

• Petri M, Joyce D, Haag K, Fava A, Goldman DW, Zhong D, Xiao S, Milstone A, Magder LS. Effect of systemic lupus erythematosus and immunosuppressive agents on COVID-19 vaccination antibody response. Arthritis Care Res. 2023; https://doi.org/10.1002/acr.25094. SLE patients, regardless of immunosuppressive therapy, have lower vaccine IgG levels compared to healthy control group

Speer C, Töllner M, Benning L, et al. Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2022;81:593–5.

Article  CAS  PubMed  Google Scholar 

Wieske L, van Dam KPJ, Steenhuis M, et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 2022;4:e338–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mrak D, Simader E, Sieghart D, et al. Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study. Ann Rheum Dis. 2022;81:1750–6.

Article  CAS  PubMed  Google Scholar 

Troldborg A, Thomsen MK, Bartels LE, et al. Time since rituximab treatment is essential for developing a humoral response to COVID-19 mRNA vaccines in patients with rheumatic diseases. J Rheumatol. 2022;49:644–9.

Article  CAS  PubMed  Google Scholar 

Bitoun S, Henry J, Desjardins D, et al. Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases. Arthritis & Rheumatology. 2022;74:927–33.

Article  CAS  Google Scholar 

Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23:186–93.

Article  CAS  PubMed  Google Scholar 

Boedecker-Lips SC, Claßen P, Kraus D, Weinmann-Menke J. Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus. Rheumatology. 2023;62:e34–5.

Article  PubMed  Google Scholar 

Fabris M, De Marchi G, Domenis R, et al. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. J Autoimmun. 2022; https://doi.org/10.1016/j.jaut.2022.102827.

Sattui SE, Liew JW, Kennedy K, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021;7:e001814.

Article